2 Beaten-Down Stocks That Still Aren't Worth Buying

The article argues that Recursion Pharmaceuticals and Sarepta Therapeutics, despite significant stock declines, remain unattractive investments. Recursion has no approved products and faces competition in AI-driven drug discovery. Sarepta struggles with safety concerns around its lead therapy Elevidys and faces an uncertain path to regaining market confidence despite some clinical progress.

07/11/2026, 4:30 PM • The Motley Fool

Generative AI in Drug Discovery: Revolutionizing Pharmaceutical Research and Development

The generative AI in drug discovery market is experiencing significant expansion, growing from $0.25 billion in 2025 to $0.33 billion in 2026, with projections to reach $0.86 billion by 2030 at a 27% CAGR. Key drivers include rising drug development costs, computational chemistry advancements, increased biological datasets, and strategic collaborations between AI firms and pharmaceutical companies. Major players are leveraging AI-driven tools for molecule generation, deep learning in drug design, and accelerated early-stage development.

07/10/2026, 10:55 AM • GlobeNewswire

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood's Ark Invest actively purchased shares in Tesla, SoFi Technologies, and Recursion Pharmaceuticals on Thursday. Tesla delivered 480,126 vehicles in Q2, exceeding analyst expectations by 74,000 units, though the stock fell 7.35% on the day. SoFi, which Ark bought every trading day this week, continues to demonstrate strong growth metrics with a Rule of 40 score of 72. Recursion Pharmaceuticals, an AI-driven drug discovery company, represents a longer-term speculative bet for Wood's portfolio.

07/05/2026, 6:03 AM • The Motley Fool

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

Moderna and Recursion Pharmaceuticals represent two distinct approaches to biotech innovation: Moderna leverages proven mRNA technology with diversifying pipeline into oncology and rare diseases, while Recursion uses AI-driven drug discovery. Despite both operating at losses, Moderna is favored for 2026 due to its established revenue base and proven formula, whereas Recursion remains in earlier development stages with revenue expected to decline due to lower milestone payments.

07/03/2026, 11:14 AM • The Motley Fool

Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market

Nvidia's venture capital arm has invested $13 million in Generate Biomedicines, a biotech company developing an AI platform for virtual drug testing. The platform addresses major pharmaceutical industry challenges by reducing development time and costs, with AI-discovered drugs showing twice the success rate in phase 1 trials. This investment signals Nvidia's confidence in the company's potential to transform the $1.8 trillion pharmaceutical market.

06/27/2026, 7:23 AM • The Motley Fool

2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying

The article examines two AI-related stocks that have experienced significant declines: Recursion Pharmaceuticals, an AI-focused biotech company using algorithms for drug discovery with promising candidates but no approved products yet, and Fiverr, a freelance platform shifting strategy toward complex, higher-value projects to counter revenue and user declines. Both present contrarian investment opportunities with substantial upside potential but carry considerable risks.

06/26/2026, 12:15 AM • The Motley Fool

The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

The AI drug discovery field is shifting focus from building the most powerful models to establishing trustworthy, connected biological data foundations. MindWalk Holdings (HYFT) has positioned itself as a leader in this 'context layer' approach with its ReefIQ and LensAI platforms, reporting 52% YoY revenue growth and its first recurring platform contract. The article examines how this represents a maturation of the sector beyond initial hype, comparing MindWalk's strategy to peers like Absci, Recursion, Schrödinger, and Certara.

06/16/2026, 8:45 AM • Benzinga

Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?

Recursion Pharmaceuticals and Schrödinger represent different approaches to AI-driven drug discovery—one biotech-focused with clinical-stage programs, the other software-first with recurring revenue. While both show strong growth (26.9% and 23.3% respectively), Recursion trades at a premium valuation (26.1x P/S) with significant losses and no approved products, while Schrödinger has a lower P/S ratio (4.3x) and improving profitability. The analyst recommends neither stock currently but would choose Schrödinger if forced to pick, citing its established software business and improving financial trajectory.

06/02/2026, 5:12 PM • The Motley Fool

Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?

Recursion Pharmaceuticals, an AI-focused biotech company, has hit a 52-week low despite partnerships with major pharmaceutical companies and Nvidia. While the company's AI-powered drug discovery platform shows promise and addresses a real problem in drug development costs and timelines, it lacks tangible clinical evidence. With no approved products and only early-stage pipeline candidates, the stock remains highly speculative and risky for most investors.

05/25/2026, 7:30 PM • The Motley Fool

Global AI in Life Sciences Market Gearing Up for Outstanding Expansion at a CAGR of ~20% by 2034 | DelveInsight

The AI in life sciences market is projected to grow from USD 2.2 billion in 2025 to USD 11.5 billion by 2034, driven by accelerated drug discovery, precision medicine adoption, and increasing healthcare data availability. North America leads with 44.78% market share, while Europe and Asia-Pacific show significant growth potential. Major pharmaceutical and technology companies are investing heavily through partnerships and AI-enabled platforms.

05/13/2026, 1:00 PM • GlobeNewswire

3 Stocks Poised to Disrupt the Healthcare Market by 2030

The healthcare industry is shifting toward data-driven, precision medicine models powered by AI and genomic data. Three companies are positioned to lead this transformation: Tempus AI is building a healthcare data platform with network effects; Recursion Pharmaceuticals is accelerating drug discovery through automation and machine learning; and Axsome Therapeutics is gaining traction with fast-acting CNS treatments, particularly its antidepressant Auvelity.

05/08/2026, 7:30 AM • The Motley Fool

Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform

Citeline and its parent company Norstella announced an expanded partnership with Recursion (NASDAQ: RXRX) to integrate real-world data and evidence capabilities into Recursion's drug discovery and development platform. The collaboration aims to improve trial design, site selection, and development decisions, with Recursion reporting 30-60% improvements in enrollment through the integrated ClinTech platform.

03/31/2026, 9:00 AM • GlobeNewswire

Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026

AI stocks have suffered significant corrections as investors reassess the technology's real-world value and cost-effectiveness. The article argues this represents the 'trough of disillusionment' phase of the Gartner Hype Cycle, which historically precedes a bullish recovery. The author recommends Oracle and Alphabet as well-positioned to capitalize on the upcoming 'slope of enlightenment' phase, while cautioning against Microsoft despite its current dominance.

03/22/2026, 1:27 PM • The Motley Fool

ARK Unplugged: How Cathie Wood Crushed the S&P 500 in 2025

ARK Invest's 2025 performance data shows the ARK Innovation ETF delivered a 35.5% return, significantly outperforming the S&P 500's 16.6% gain. Top performers included Robinhood Markets (+204%), Palantir Technologies (+135%), and AMD (+77%), while notable losers were The Trade Desk (-68%), Recursion Pharmaceuticals (-40%), and Twist Bioscience (-32%). ARK maintains conviction in underperforming positions based on long-term platform objectives.

02/24/2026, 3:52 PM • Benzinga

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood's Ark Invest added to positions in Figma, CoreWeave, and Recursion Pharmaceuticals on Friday as all three growth stocks trade significantly below their 2025 highs. Figma showed strong Q4 results with 40% revenue growth and improved margins, while CoreWeave benefits from AI infrastructure demand. Recursion faces headwinds after Nvidia exited its stake, though the company remains a clinical-stage AI-driven biotech play.

02/22/2026, 10:02 AM • The Motley Fool